Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 11/20 | 0.66 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.50 |
| ▸ | RIPK3 | Q9Y572 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701111 | 0.97 | CSNK1D (0.69) | CSNK1DRIPK1RIPK3DYRK2CYP3A4 | |
| SCHEMBL15701115 | 0.89 | MAPT (0.51) | CSNK1DMAPTL3MBTL1DYRK2 | |
| SCHEMBL15701137 | 0.86 | DHODH (0.52) | CSNK1DMAPTMEN1KMT2A | |
| SCHEMBL15701257 | 0.86 | DHODH (0.52) | CSNK1DMAPTMEN1KMT2A | |
| SCHEMBL15701149 | 0.86 | CSNK1D (0.51) | CSNK1DRIPK1RIPK3MAPTMEN1 | |
| SCHEMBL15701156 | 0.85 | RIPK1 (0.49) | CSNK1DRIPK1RIPK3MAPTL3MBTL1 | |
| SCHEMBL15701144 | 0.85 | CASP3 (0.51) | CSNK1DCYP2C9 | |
| SCHEMBL15701025 | 0.85 | CSNK1D (0.50) | CSNK1DCYP3A4CYP2C9 | |
| SCHEMBL15701256 | 0.84 | CSNK1D (0.49) | CSNK1DMAPTMEN1KMT2ACYP3A4 | |
| SCHEMBL15701151 | 0.84 | CSNK1D (0.57) | CSNK1DRIPK1MAPTDYRK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914592-B1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INT (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-9334249-B2 | Inhibitors of cytomegalovirus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-10 | — | — | US | disclosed |
| US-20150284348-A1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-08 | — | — | US | disclosed |
| WO-2014070979-A1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284348-A1 | INHIBITORS OF CYTOMEGALOVIRUS | CDKN1A, CCNA1, IFNAR1 | CSNK1D 247/4885RIPK1 780/4885RIPK3 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.